We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OriGene Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
News

OriGene Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China

OriGene Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
News

OriGene Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OriGene Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OriGene Technologies, Inc. has announced it has raised an additional $6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P&A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community.

With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins.

Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation.

With OriGene's China monoclonal antibody production capacity and these genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.

This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.
Advertisement